中国P站

Biopsy; Tissue acquisition; Ultrasound-guided biopsy; Image-guided biopsy; Precision oncology; Liquid biopsy; Minimally invasive techniques; Digital pathology; Artificial Intelligence; Non-Small Cell Lung Cancer; Pancreatic masses; Brain lesions; Kidney biopsy; Liver biopsy; Diagnostic accuracy

Introduction

Tissue biopsy serves as a cornerstone in diagnostic medicine, providing indispensable insights into disease pathology for accurate diagnosis and effective treatment planning. Over time, the methodologies for tissue acquisition have undergone significant evolution, driven by the need for enhanced precision, reduced invasiveness, and improved diagnostic yield across a broad spectrum of clinical applications. Understanding these advancements is crucial for modern medical practice, as they directly impact patient care and outcomes. For example, the field of tissue biopsy has significantly evolved, detailing advanced methods and expanded applications to ensure more accurate and less invasive tissue acquisition for diagnosis. It's about getting the right sample, precisely [1].

This foundational technique is widely used, and continuous updates keep practices current. Beyond general applications, the interplay between liquid and tissue biopsies is critical in tackling Non-Small Cell Lung Cancer, a key area in oncology. This balance clarifies when each approach excels for initial diagnosis, identifying actionable mutations, and monitoring treatment response, which is vital for optimizing patient care [2].

Clinicians often weigh the benefits and limitations of both methods depending on the clinical scenario. Image-guided percutaneous biopsy stands as an essential tool in modern diagnostics. It encompasses various techniques, addressing ongoing debates surrounding their application, and provides a comprehensive overview of how these procedures are performed and optimized for both safety and diagnostic yield [3].

These methods allow for precise targeting of lesions, reducing risks associated with blind biopsies. In precision oncology, obtaining a tissue biopsy transcends mere diagnosis; it's about securing a sample robust enough for detailed molecular profiling. This involves understanding crucial factors for maintaining sample quality and interpretability, which is absolutely vital for guiding targeted therapies and delivering truly personalized patient care [4].

The integrity of the sample directly influences the accuracy of subsequent molecular analyses. For complex brain lesions, stereotactic biopsy is frequently the chosen diagnostic method. Studies provide practical insights into the technical aspects of these biopsies and, importantly, their diagnostic success rates in real-world clinical settings, underscoring the precision required for complex neurological cases [5].

This technique minimizes trauma while maximizing diagnostic yield in delicate anatomical areas. For pancreatic masses, Endoscopic Ultrasound-guided Tissue Acquisition (EUS-TA) has garnered significant attention. Systematic reviews and meta-analyses rigorously evaluate EUS-TA's diagnostic accuracy, offering robust evidence of its effectiveness for diagnosing these challenging conditions [6].

This procedure combines imaging with tissue sampling, enhancing diagnostic capabilities. Native kidney biopsies are crucial for diagnosing renal diseases, necessitating a thorough understanding of their safety profile. Large-scale single-center studies, involving numerous patients, provide solid data on both the effectiveness and potential risks associated with the procedure, offering important insights for clinicians in treatment planning [7].

Balancing diagnostic needs with potential complications is a key consideration. The landscape of biopsy is undergoing significant transformation, with a clear shift towards less invasive techniques. Emerging technologies in minimally invasive tissue biopsy are highlighted, showcasing innovations designed to make sample collection safer, more precise, and less uncomfortable for patients, pushing the boundaries of diagnostic medicine [8].

These advancements promise to improve patient experience and recovery times. Liver biopsy, despite its invasive nature, continues to be a key diagnostic tool for various liver diseases. Practical guides clearly outline when a liver biopsy is necessary and, crucially, when it should be avoided, assisting clinicians in navigating the complexities of liver diagnostics and appropriate clinical scenarios [9].

This guidance is essential for risk-benefit assessment. Finally, the integration of Artificial Intelligence (AI) into pathology represents a transformative shift for tissue biopsy analysis. Articles delve into how AI is revolutionizing biopsy processing in digital pathology, promising faster, more accurate diagnoses, and assisting pathologists in identifying subtle features, pointing to a future of enhanced diagnostic efficiency and precision [10].

This technological leap promises to augment human expertise significantly.

Description

Tissue acquisition methods are foundational in modern medicine, continually refined for enhanced precision and reduced invasiveness across numerous specialties. Ultrasound-guided tissue biopsy, for example, has become a core technique, widely recognized for its ability to provide accurate and less invasive tissue samples crucial for diagnosis [1]. This evolution ensures that clinicians can obtain the right sample precisely, a critical step in effective patient management. Similarly, image-guided percutaneous biopsies represent an essential diagnostic tool, with ongoing discussions surrounding various techniques and their optimal application to maximize safety and diagnostic yield [3]. These advancements underscore a commitment to refining diagnostic processes.

In the complex realm of oncology, biopsy techniques are pivotal, not just for initial diagnosis but also for informing targeted therapies and monitoring disease progression. The strategic use of both liquid and traditional tissue biopsies, particularly in cases like Non-Small Cell Lung Cancer, highlights a sophisticated approach to diagnosis and management. Liquid biopsies offer unique advantages for identifying actionable mutations and monitoring treatment response, complementing the comprehensive insights provided by tissue samples [2]. Here’s the thing, for precision oncology, the quality and interpretability of the tissue biopsy are paramount. It’s not just about getting a sample; it's about ensuring it is robust enough for detailed molecular profiling, which is absolutely vital for guiding personalized patient care [4].

Specialized biopsy procedures cater to specific anatomical challenges and disease contexts, demonstrating the breadth of current capabilities. Stereotactic biopsy, for instance, is the preferred method for diagnosing challenging brain lesions, offering critical technical insights and demonstrating high diagnostic success rates in complex neurological cases [5]. For pancreatic masses, Endoscopic Ultrasound-guided Tissue Acquisition (EUS-TA) stands out, with systematic reviews and meta-analyses confirming its high diagnostic accuracy and effectiveness [6]. Beyond cancerous conditions, the safety and efficacy of diagnostic procedures remain key. A large single-center study on native kidney biopsies, involving numerous patients, provided solid data on both the effectiveness and potential risks, offering crucial insights for clinicians balancing diagnostic benefits with potential complications [7].

The future of tissue biopsy is clearly moving towards less invasive and more technologically integrated approaches. New technologies in minimally invasive tissue biopsy promise to make sample collection safer, more precise, and significantly less uncomfortable for patients, pushing the boundaries of what is possible in diagnostic medicine [8]. These innovations aim to reduce patient burden while maintaining diagnostic integrity.

Furthermore, understanding the appropriate clinical scenarios for each procedure is essential; for liver biopsy, practical guides clearly delineate its indications and, equally important, its contraindications, helping clinicians navigate complex diagnostic decisions effectively [9]. The biggest game-changer involves the integration of Artificial Intelligence (AI) into pathology. AI is revolutionizing biopsy processing in digital pathology, leading to faster, more accurate diagnoses and aiding pathologists in identifying subtle features that might otherwise be missed, thereby enhancing diagnostic efficiency and precision significantly [10]. This convergence of advanced techniques and Artificial Intelligence is shaping a transformative future for diagnostic pathology.

Conclusion

Tissue biopsy is a fundamental diagnostic technique, continuously evolving to be more precise and less invasive across various medical specialties. Early advancements like ultrasound-guided and image-guided percutaneous biopsies have significantly improved tissue acquisition, offering greater accuracy and safety. In oncology, the choice between liquid and tissue biopsies is critical, especially for conditions like Non-Small Cell Lung Cancer, guiding initial diagnosis and treatment monitoring. Precision oncology specifically relies on high-quality tissue samples for detailed molecular profiling, making sample integrity vital for personalized care. Specialized procedures like stereotactic biopsy for brain lesions and Endoscopic Ultrasound-guided Tissue Acquisition (EUS-TA) for pancreatic masses highlight the adaptability of biopsy techniques to complex anatomical challenges. Assessing the safety and efficacy of procedures, such as native kidney biopsies, remains paramount for patient care. Looking ahead, the field is moving towards minimally invasive approaches, promising safer and more comfortable sample collection. Furthermore, integrating Artificial Intelligence (AI) into digital pathology is set to revolutionize biopsy analysis, enhancing diagnostic speed and accuracy. These developments collectively underline a significant push towards optimizing diagnostic yield while prioritizing patient well-being and advancing personalized medicine.

References

1. Luca S, Luca C, Nicola G (2021) .Ultrasonography 40:3-21.

   , ,

2. Julien R, Christophe C, Federica F (2020) .Cells 9:1083.

   , ,

3. Petr Z, Jan Z, Dana M (2021) .Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 165:1-13.

   , ,

4. Tilo G, Maike L, Falko F (2022) .Cancers (Basel) 14:3089.

   , ,

5. Mohammad IK, C SK, Neeraj K (2021) .J Clin Neurosci 87:93-98.

   , ,

6. Jianli H, Jian L, Jie D (2021) .Endosc Int Open 9:E11-E22.

   , ,

7. Xin L, Ping L, An-yuan P (2021) .Ren Fail 43:110-117.

   , ,

8. Yu L, Bowen W, Chuan L (2023) .Adv Sci (Weinh) 10:e2204558.

   , ,

9. Angelo S, Luca M, Luca C (2020) .J Clin Med 9:3953.

   , ,

10. Kashif A, Zaeem K, Khurram K (2023) .Sensors (Basel) 23:3671.

    , ,